Kelun-Biotech Will Present an Update on SKB264 at 2021 ESMO

Members from our parent company, Kelun-Biotech, will attend the 2021 ESMO Annual Meeting held online from September 16-21. We will present the latest results from our ongoing Phase 1 international, multicenter clinical trial of SKB264 (TROP2-ADC) in patients with locally advanced or metastatic solid tumors. The presentation is expected to occur on September 17 from 14:20-14:30 CET (Channel 7). Professor Jordi Rodon Ahnert will present the results in an oral report on behalf of the research team. Please join us for the exciting update!

Title: 514O- An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors
Presentation Number: 514O
Speakers: Jordi Rodon (Houston, United States of America)
Lecture Time: 14:20-14:30 CET